Real Tech Fund Enables Automatic Heart Disease Diagnosis Assistance and Telemedicine
Invested in "AMI Co., Ltd.", which develops medical devices

Euglena Investment Co., Ltd.

　Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) has invested in AMI Co., Ltd. (hereinafter referred to as AMI) as a new investment destination for the R & D-specialized venture capital fund "Real Tech Fund". We would like to inform you that we have made an investment.　

　AMI is developing a highly accurate automatic heart disease diagnosis assist device "super stethoscope" by extracting and synthesizing the generation timing of cardiac action potential and digitized auscultation sound. The "super stethoscope" aims to be a medical device that can be used by the patient himself, such as a blood pressure monitor, and is also expected to be applied to telemedicine.
　The Real Tech Fund will underwrite the shares issued by AMI through a third-party allotment, and the 2017 “Research” by the National Research and Development Corporation New Energy and Industrial Technology Development Organization (NEDO), which was adopted by AMI. Development-type venture support business / Commercialization support for R & D-type ventures in the seed period ”As a certified VC of the subsidy business, we support the company's R & D, sales and marketing activities.
　The details are as follows.

About investment inAMI Co., Ltd.

■ About the outline and support contents of AMI Co., Ltd.
　Date of establishment: November 2, 2015
　location　: 5-98 Hamamatsucho, Minamata City, Kumamoto Prefecture
　Representative　: Representative Director Shinpei Ogawa
　Business: Development and sales of telemedicine-compatible stethoscope with automatic heart disease diagnosis assist function
　HP　　: Http://ami-kumamoto.com/
　Support content: Promotion of cooperation with fund-funded companies, support for research and development, sales and marketing activities
　Investment period: May 2018

■ About Realtech Fund (HP: http://www.realtech.fund)
　Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 30 participating companies and a fund size of 9.4 billion yen (as of June 2018), it is Japan's largest fund specializing in real tech. We are investing in and nurturing real-tech ventures together with the operating companies that are our investors.

​ ​

-Contact for inquiries from the press-
Public Relations Officer, Euglena Investment Co., Ltd.